Thermo Fisher Scientific Alirocumab Recombinant Human Monoclonal Antibody
인간 PCSK9을 표적으로 하는 재조합 인간 단클론 항체. ELISA 등 연구용 분석에 적합. 낮은 엔도톡신 수준(<0.01 EU/µg)으로 정제. 단백질 A/G로 정제된 액상 형태. 고콜레스테롤 연구 및 PCSK9 억제 기전 연구에 활용 가능.
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Alirocumab Recombinant Human Monoclonal Antibody
Applications
- ELISA (Assay-dependent)
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Human / IgG1, kappa |
| Expression System | CHO cells |
| Class | Recombinant Monoclonal |
| Type | Antibody |
| Immunogen | Human PCSK9 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Concentration | 2.18 mg/mL |
| Purification | Protein A/G |
| Storage Buffer | PBS, pH 7.4 |
| Contains | No preservative |
| Storage Conditions | -20°C, Avoid Freeze/Thaw Cycles |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
| RRID | AB_2911106 |
Product Specific Information
- Endotoxin level: < 0.01 EU/µg by LAL method
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Store at 2–8°C for one week.
- Store at -20 to -80°C for twelve months from the date of receipt.
Target Information
Alirocumab is a biopharmaceutical that received FDA approval in July 2015 as a second-line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin therapy.
It is a human monoclonal antibody belonging to the PCSK9 inhibitor family, a novel class of anticholesterol therapeutics.
Alirocumab was the first agent in this class to receive FDA approval. The approval required further clinical trials to assess efficacy and safety.
PCSK9 inhibition promotes increased LDL-C clearance from the bloodstream.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기
문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.